1 Volatile Stock to Target This Week and 2 We Turn Down

Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.

These stocks can be a rollercoaster, and StockStory is here to guide you through the ups and downs. Keeping that in mind, here is one volatile stock that could deliver huge gains and two that could just as easily collapse.

Two Stocks to Sell:

Repligen (RGEN)

Rolling One-Year Beta: 1.40

With over 13 strategic acquisitions since 2012 to build its comprehensive bioprocessing portfolio, Repligen (NASDAQ:RGEN) develops and manufactures specialized technologies that improve the efficiency and flexibility of biological drug manufacturing processes.

Why Is RGEN Risky?

1. Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
2. Efficiency has decreased over the last five years as its adjusted operating margin fell by 17.8 percentage points
3. Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results

At $165.01 per share, Repligen trades at 85.9x forward P/E. Read our free research report to see why you should think twice about including RGEN in your portfolio.

Amentum (AMTM)

Rolling One-Year Beta: 1.09

With operations spanning approximately 80 countries and a workforce of specialized engineers and technical experts, Amentum Holdings (NYSE:AMTM) provides advanced engineering and technology solutions to U.S. government agencies, allied governments, and commercial enterprises across defense, energy, and space sectors.

Why Is AMTM Not Exciting?

1. Sizable revenue base leads to growth challenges as its 2.4% annual revenue increases over the last three years fell short of other business services companies
2. Estimated sales decline of 1.5% for the next 12 months implies a challenging demand environment
3. Below-average returns on capital indicate management struggled to find compelling investment opportunities

Amentum’s stock price of $29.06 implies a valuation ratio of 12.2x forward P/E. To fully understand why you should be careful with AMTM, check out our full research report (it’s free for active Edge members).

One Stock to Buy:

Medpace (MEDP)

Rolling One-Year Beta: 1.19

Founded in 1992 as a scientifically-driven alternative to traditional contract research organizations, Medpace (NASDAQ:MEDP) provides outsourced clinical trial management and research services to help pharmaceutical, biotechnology, and medical device companies develop new treatments.

Why Do We Love MEDP?

1. Core business is healthy and doesn’t need acquisitions to boost sales as its organic revenue growth averaged 15.1% over the past two years
2. Share repurchases over the last five years enabled its annual earnings per share growth of 34.2% to outpace its revenue gains
3. Market-beating returns on capital illustrate that management has a knack for investing in profitable ventures

Medpace is trading at $547.32 per share, or 34.5x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it’s free for active Edge members.

Stocks We Like Even More

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.